STRUCTURAL BIOLOGY FOR THE DEVELOPMENT OF SARS-COV-2 VACCINES

Through our expertise in structural biology of proteins, we participated, in collaboration with the Finlay Vaccine Institute of Cuba, in the development of SOBERANA vaccines against COVID19, based on the recombinant protein RBD, SARS-CoV-2 spike protein binding domain on ACE2 receptor

The recombinant RBD protein is used in SOBERANA vaccines (https://hal.science/hal-03327027) either as a dimer (https://doi.org/10.1039/d1cb00200g) or conjugated with tetanus anatoxin (https://hal.science/hal-03443835).